Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 2 Date: 16 Sep 2024
Reviewer's report:
I thank the authors for having taking into accounts my comments about Janjigian 2021 and
Janjigian 2024.
However, thanks to comments from Reviewer 3 , I figured out that the authors also included
redundant analyses for ATTRACTION-2 and ATTRACTION-4 trials. These redundancies are
not adressed in the  revised manuscript as the analyses still includes the redundant data about
those trials.
A subgroup analysis cannot be considered as a different study from the original one.
Therefore, I don't believe this study is bringing more information than ATTRACTION-2 itself.
Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 2 Date: 16 Sep 2024
Reviewer's report:
I thank the authors for having taking into accounts my comments about Janjigian 2021 and
Janjigian 2024.
However, thanks to comments from Reviewer 3 , I figured out that the authors also included
redundant analyses for ATTRACTION-2 and ATTRACTION-4 trials. These redundancies are
not adressed in the  revised manuscript as the analyses still includes the redundant data about
those trials.
A subgroup analysis cannot be considered as a different study from the original one.
Therefore, I don't believe this study is bringing more information than ATTRACTION-2 itself.
Please review this paper.
user
Title: Efficacy and Safety of Nivolumab in Advanced Gastric and Gastroesophageal Junction
Cancer: A Meta-Analysis of Randomized Controlled Trials
Version: 2 Date: 16 Sep 2024
Reviewer's report:
I thank the authors for having taking into accounts my comments about Janjigian 2021 and
Janjigian 2024.
However, thanks to comments from Reviewer 3 , I figured out that the authors also included
redundant analyses for ATTRACTION-2 and ATTRACTION-4 trials. These redundancies are
not adressed in the  revised manuscript as the analyses still includes the redundant data about
those trials.
A subgroup analysis cannot be considered as a different study from the original one.
Therefore, I don't believe this study is bringing more information than ATTRACTION-2 itself.
assistant